lenvatinib

Org: Memorial Sloan Kettering Cancer Center, University of Bari "A. Moro" and Policlinico Consorziale, Kyushu University, Texas Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea,

Abstract

Atezolizumab + bevacizumab versus lenvatinib as first-line systemic therapy for treatment of hepatocellular carcinoma in a real-world population: Outcomes from the HCC CHORD database.

Org: Halifax, NS, Canada, Winnipeg, MB, Canada,

Abstract

RNA expression-based hypoxia score as a prognostic and predictive biomarker in hepatocellular carcinoma.

Org: JC Walter Jr Center for Transplantation and Sherrie and Alan Conover Center for Liver Disease and Transplantation,

Abstract

Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.

Org: University Hospital Zurich, Aix-Marseille University CHU Timone, Hôpital de la Timone, Department of Cancer Medicine, Gustave Roussy Cancer Centre, Gustave Roussy Cancer Campus,

Abstract

BGB-A317-212: A multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors.

Org: Jiangsu Cancer Hospital, Peking University First Hospital, Zhejiang Provincial People's Hospital, The First Affiliated Hospital of Nanchang University Branch Donghu, The People's Hospital of Guangxi Zhuang Autonomous Region,

Abstract

Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.

Org: The University of Texas HSC at San Antonio Cancer Therapy and Research Center,

Abstract

ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy.

Org: Taipei, Taiwan, Sutter/California Pacific Medical Center, Nanjing Bayi Hospital, Nanjing, Jiangsu, China, Ibaraki, Japan,

Abstract

Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC).

Org: Geffen School of Medicine, Weill Cornell Medical Center, Toranomon Hospital Kajigaya,

Abstract

Efficacy and safety of envafolimab plus lenvatinib combined with TACE in initially unresectable hepatocellular carcinoma: An open-label, single-arm, phase II study.

Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, China,

Abstract

Hepatic artery infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for initial unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus: A prospective, single-arm phase II trial.

Org: The First Affiliated Hospital of Chongqing Medical University,

Abstract

Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (SHATA-001).

Org: Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China,

Abstract

Cadonilimab plus lenvatinib in patients with advanced endometrial cancer: A multicenter, single-arm, phase II trial.

Org: The Third Affiliated Hospital Kunming Medical University,

Abstract

AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC).

Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, University of Chicago Medicine, UCSF Helen Diller Family Comprehensive Cancer Center,

Abstract

Lenvatinib (len) plus pembrolizumab (pembro) in patients with advanced melanoma that progressed on anti–PD-(L)1 therapy: Over 4 years of follow-up from the phase 2 LEAP-004 study.

Org: John Wayne Cancer Institute, Centre hospitalier de l’Université de Montréal (CHUM), Centre de recherche du CHUM, Skåne University Hospital Comprehensive Cancer Centrer and Lund University, Hospital General Universitario Gregorio Marañón and CIBERONC,

Abstract

GEMINI-Hepatobiliary: A phase 2 study of novel first-line immuno-oncology-based treatments in patients with advanced hepatobiliary cancers.

Org: NTUH Cancer Hospital, B2F Samsung Comprehensive Cancer Center, Jiangsu, China, Shatin, Hong Kong,

Abstract

Belzutifan plus lenvatinib (len) for Chinese patients (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Preliminary results of cohort 1 of the phase 1 LITESPARK-010 study.

Org: The Affiliated Hospital of Nanjing University Medical School, MSD (China) Co., Ltd.,

Abstract

Outcomes of reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.

Org: Kaiser Permanente San Diego, Kaiser Permanente National Drug Use Management,

Abstract

FDA analysis of immune checkpoint inhibitors in combination with vascular endothelial growth factor tyrosine kinase inhibitors in the second-line treatment of patients with advanced non-small cell lung cancer.

Org: U.S. Food and Drug Administration, Silver Spring, MD, Office of Oncologic Diseases, Center for Drug Evaluation and Research, Oncology Center of Excellence,

Abstract

Stereotactic body radiotherapy (SBRT) combined with transcatheter arterial chemoembolization (TACE) and tyrosine kinase inhibitors (TKIs) versus TACE and TKIs alone for unresectable hepatocellular carcinoma (uHCC) with portal vein tumor thrombus (PVTT): A randomized controlled trial.

Org: State Key Laboratory of Biotherapy and Cancer Center, Department of Liver Transplantation Center, Division of Liver Surgery, Laboratory of Liver Surgery, Collaborative Innovation Center of Biotherapy,

Abstract

Patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) with BRAF V600E and/or K601E mutation status: A real-world view of effectiveness of lenvatinib monotherapy.

Org: Adelphi Real World,

Abstract

Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer.

Org: Department of Physiology and Pharmacology, Faculty of Medicine, Tel-Aviv University, Department of Physiology and Pharmacology, Faculty of Medicine, Tel Aviv University,

Abstract

Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).

Org: Liver Cancer Institute, Department of Hepatic Surgery II, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Department of Hepatic Surgery V, Center of Hepato-Pancreato-Biliary Surgery,

Abstract

PD-1 inhibitor (sintilimab) and lenvatinib plus TACE-HAIC as conversion therapy for initially unresectable HCC: A single-arm, phase 2 clinical trial (PLATIC).

Org: Department of Liver Surgery,

Abstract

Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study.

Org: University of Miami Hospital and Clinics, Cancer Research Services, New York Oncology Hematology, Moscow City Clinical Oncology Hospital No. 1, Alexandra General Hospital,

Abstract

A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC).

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Indiana University Simon Comprehensive Cancer Center, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, University of Chicago, Chicago, IL, Department of Medicine, Division of Hematology and Oncology, The Medical College of Wisconsin, Milwaukee, WI, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Mary Crowley Cancer Research, Dallas, TX, AdventHealth Cancer Institute, Orlando, FL, Sarah Cannon Research Institute, Nashville, TN, St. Jude Crosson Cancer Institute/Providence Medical Foundation, Fullerton, CA, Fort Wayne Medical Oncology - West Jefferson Office, Fort Wayne, IN, Scholar Rock Inc., Cambridge, MA, Scholar Rock, Cambridge, MA, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,

Abstract

Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma.

Org: Weill Medical College at Cornell University,

Abstract

Cobimetinib plus atezolizumab for RAS and NF1/2-mutated poorly differentiated thyroid carcinoma.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX,

Abstract

Neoadjuvant pembrolizumab plus lenvatinib in patients with resectable stage III melanoma (NeoPele): Analysis of tumor microenvironment (TME) correlated to pathological response.

Org: Melanoma Institute Australia, Faculty of Medicine and Health, The University of Sydney, Charles Perkins Centre, The University of Sydney, The University of Sydney, Blacktown Hospital,

Abstract

Neoadjuvant pembrolizumab and lenvatinib in resectable mucosal melanoma: NeoPlus study update.

Org: Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Department of Melanoma and Sarcoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Haidian District, China,

Clinical trial

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Status: Recruiting, Estimated PCD: 2025-01-15

Abstract

A prospective study of radiofrequency ablation combined with systematic neoadjuvant therapy in the treatment of recurrent hepatocellular carcinoma (RANT study).

Org: The First Affiliated Hospital of Army Military Medical University,

Abstract

Second-line systematic strategy options for the progression of lenvatinib plus tislelizumab treating unresectable hepatocellular carcinoma: A retrospective study.

Org: National Cancer Center Hospital East, Kashiwa, Japan, Cancer Hospital of Chinese Academy of Medical Sciences, Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,

Abstract

Transarterial chemoembolization combined with donafenib or lenvatinib as first-line treatment for unresectable hepatocellular carcinoma: A single-center real-world retrospective study.

Org: The Third Affiliated Hospital of Sun Yat-sen University,

Abstract

Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: Lenvamel, a multicenter retrospective study of the French Group of Skin Cancers.

Org: Service de dermatologie, CHU de Nice, Nice, France, Service de Dermatologie, Centre Hospitalier Universitaire and Université Franche Comté, Inserm 1098 RIGHT, Besançon, France, Hôpital Avicenne – APHP, Bobigny, France, Service de Dermatologie, Hôpital Avicenne, Université Sorbonne Paris Nord, Bobigny, France, Service de Dermatologie, CHU Bordeaux, Bordeaux, France,

Abstract

Hepatic artery infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced hepatocellular carcinoma with portal vein tumor thrombus: A single center retrospective study.

Org: Department II of Interventional Radiology,

Abstract

A single-arm, prospective study on the efficacy and safety of TACE-HAIC combined with lenvatinib and tislelizumab in the treatment of unresectable hepatocellular carcinoma.

Org: The Second People's Hospital of Yibin, Yibin, China,

Abstract

Atezolizumab plus taxane chemotherapy for the treatment of non-BRAF, non-RAS mutated anaplastic thyroid carcinoma: Final analysis.

Abstract

Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).

Org: Alberta, Canada, Sunnybrook Odette Cancer Centre,

Abstract

Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC).

Org: Medical Oncology, Vall d'Hebron Institute of Oncology, Division of Medical Oncology, National Cancer Centre Singapore,

Abstract

Tislelizumab in combination with GEMOX and lenvatinib for conversion therapy of unresectable extrahepatic biliary tract carcinoma (eBTC): A prospective, single-arm, phase 2 study.

Org: Department of Organ transplantation, the Third Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Faculty of Hepatopancreatobiliary Surgery, the First Medical Center of Chinese People’s Liberation Army (PLA) General Hospital,

Abstract

Utilizing stereotactic body radiation therapy in combination with tyrosine kinase inhibitors for therapeutic benefit in thyroid cancer.

Org: Northwell Health Department of Radiation Medicine,

Abstract

Envafolimab in combination with lenvatinib and albumin paclitaxel for previously treated advanced gastric/gastroesophageal junction adenocarcinoma: Preliminary analysis of a phase II, two-cohort study.

Org: Department of Oncology, Shanghai Medical College, Fudan University, Shangai, China, Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shangai, China,

Abstract

A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.

Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cleveland Clinic Taussig Cancer Instititute, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,

Abstract

CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.

Org: Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Division of Hepato-Gastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan,

Abstract

Lenvatinib, gemcitabine, and oxaliplatin for 67 patients with fibrolamellar carcinoma.

Org: FibroFighters Foundation, NY Presbyterian, St. George Hospital, Helen DeVos Children’s Hospital,

Abstract

Neoadjuvant tislelizumab combined with lenvatinib plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase II trial.

Org: The First Affiliated Hospital of Army Military Medical University,

Abstract

Preclinical antitumor efficacy of ETN101, a novel oral anticancer agent with Wnt/ß-catenin signaling inhibition, TME modulation, and VEGFR2 targeting for advanced hepatocellular carcinoma treatment.

Org: Daegu-Gyeongbuk Medical Innovation Foundation,

Abstract

Efficacy and safety of regorafenib plus ICIs as second-line treatment in advanced HCC post-frontline treatment failure: A real-world study from a single center.

Org: PLA General Hospital,

Abstract

Comparing the efficacy and safety of TACE combined with donafenib or lenvatinib in the treatment of unresectable hepatocellular carcinoma.

Org: University of Science and Technology of China,

Abstract

Efficacy and safety of envafolimab plus lenvatinib combined with etoposide in recurrent ovarian, peritoneal, and fallopian tube cancer: An open-label, single-arm study—The ENLEN-OC-001 study.

Org: The Affiliated Zhongda Hospital,

Abstract

Lenvatinib (Lenv) plus tislelizumab (Tis) combined with or without transarterial chemoembolization (TACE) in first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, non-randomized, open-label, phase II cohort study.

Org: State Key Laboratory of Complex Severe and Rare Diseases, Division of Pulmonary and Critical Care Medicine, State Key Laboratory of Severe and Rare Diseases,

Abstract

TACE combined with tislelizumab and lenvatinib in the treatment of advanced liver cancer: A real world study.

Org: Department of General Surgery (Hepatopancreatobiliary Surgery), Affiliated Hospital of Southwest Medical University, Luzhou, The Affiliated Hospital of Southwest Medical University, Luzhou,

Abstract

A real-world experience of hepatic arterial infusion chemotherapy combined with tislelizumab and lenvatinib for unresectable hepatocellular carcinoma with type IV portal vein tumor thrombus.

Org: Department II of Interventional Radiology,

Abstract

Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A single-arm, open-label, phase II study (ENLIGHTEN study).

Org: First People’s Hospital of Foshan, Foshan First People's Hospital,

Abstract

Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).

Org: Fred Hutchinson Cancer Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Division of Hematopathology, Mayo Clinic, Rochester, MN, Virginia Commonwealth University School of Medicine,

Abstract

A retrospective analysis of efficacy and safety of lenvatinib combined with PD-1 inhibitor and chemotherapy in advanced biliary tract cancer (BTC).

Org: The Fifth Medical Center of PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group,

Abstract

Effect of triplet regimen (single-agent chemotherapy plus anti-PD-1 antibody and tyrosine kinase inhibitors) on survival compared to chemotherapy in the second-line treatment of advanced biliary tract cancer: A retrospective analysis.

Org: the Naval Medical University,

Abstract

Changing treatment patterns for hepatocellular carcinoma: A SEER-Medicare study.

Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Dana Farber Cancer Institute, Boston, MA, Dana-Farber Cancer Institute, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,

Clinical trial

A Phase II Study of Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-01)

Status: Recruiting, Estimated PCD: 2024-08-16

Clinical trial

A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) With Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010)

Status: Recruiting, Estimated PCD: 2027-03-09

Clinical trial

A Phase 1b Dose-escalation and Cohort-expansion Study of the Safety/Tolerability, and Efficacy of Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2025-03-28

Clinical trial

Efficacy and Safety of Albumin-bound Paclitaxel-Lenvatinib-Pembrolizumab in Advanced Nonsquamous NSCLC Patients After Progression to First-line Anti-PD-1/L1 Inhibitor With Platinum-doublet Chemotherapy

Status: Not yet recruiting, Estimated PCD: 2024-10-01

Clinical trial

Icaritin Soft Capsule Combined With Lenvatinib and Transcatheter Arterial Chemoembolization（TACE） for the Treatment of Hepatocellular Carcinomaunresectable, Non-metastatic Hepatocellular Carcinoma

Status: Not yet recruiting, Estimated PCD: 2025-05-01

Clinical trial

A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma

Status: Active (not recruiting), Estimated PCD: 2026-09-30

Clinical trial

A Prospective, Single-arm Clinical Study of FOLFOX Combined With Lenvatinib as Adjuvant Chemotherapy to Prevent Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria

Status: Not yet recruiting, Estimated PCD: 2027-12-31

Abstract

A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.

Org: Memorial Sloan Kettering Cancer Center,

Abstract

Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT.

Org: Sutter/California Pacific Medical Center, Marqués de Valdecilla University Hospital, IDIVAL, The Chinese University of Hong Kong, IRCCS Azienda Ospedaliero-Universitaria di Bologna - Istituto di Ematologia “Seràgnoli”,

Abstract

NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.

Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma Oncology, Peking University Cancer Hospital & Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology,Peking University Cancer Hospital & Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma & Sarcoma,Peking University Cancer Hospital & Institute, Beijing, China,

Abstract

Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study.

Org: The First Affiliated Hospital of Fujian Medical University, Fujian Provincial Hospital, Zhangzhou Hospital Affiliated to Fujian Medical University, Xiamen Hospital of Traditional Chinese Medicine, Mengchao Hepatobiliary Hospital of Fujian Medical University,

Abstract

Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first line therapy.

Org: Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, New York, NY, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, NY, NY, Mount Sinai Health System, NY, NY, Icahn School of Medicine at Mount Sinai, New York, NY, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, NYU, New York, NY, NYU Grossman School of Medicine, Department of Population Health, Division of Biostatistics, New York, NY,

Abstract

Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer.

Org: West Cancer Center & Research Institute, University of Chicago, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Massachusetts General Hospital,

Abstract

Efficacy and safety of IBI110 in combination with sintilimab and lenvatinib in first-line of advanced hepatocellular carcinoma: Preliminary results from a phase Ib study.

Org: Peking University Cancer Hospital & Institute, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Union Hospital Tongji Medical College Huazhong University of Science and Technology, The First Hospital with Nanjing Medical University Jiangsu Province Hospital,

Abstract

Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.

Org: FDA/CDER, U.S. Food and Drug Administration, US Food and Drug Administration, Oncology Center of Excellence, Office of New Drugs,

Abstract

Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.

Org: Gustave Roussy Département d'Organisation du Parcours Patient, Vanderbilt University Medical Center, Jewish General Hospital Stroll Cancer Prevention Centre, Queensland Health, Ramón y Cajal University Hospital,

Abstract

A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer.

Org: Massachusetts Eye and Ear Infirmary, Harvard Medical School, Northshore University Healthsystem, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,

Abstract

Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.

Org: Humanitas University, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milano), Italy, IRCCS Humanitas Research Hospital, Rozzano, Italy, Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy, Hospital Clínic Barcelona,

Abstract

Correlation of cardiovascular disease with racial disparities in endometrial cancer outcomes.

Org: Medical College of Wisconsin, Froedtert and the Medical College of Wisconsin Workforce Health, Milwaukee, WI,

Abstract

A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.

Org: MSKCC, Memorial Sloan Kettering Cancer Center,

Abstract

Ex-vivo analysis of programmed cell death on fibrolamellar carcinoma.

Org: Rush University Medical School, FibroFighters Foundation, Nagourney Cancer Institute, FibroFighters.org, Rush University Medical Center,

Abstract

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.

Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China National Biotec Group, Shandong Suncadia Medicine,

Abstract

A phase 1b study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients with advanced hepatocellular carcinoma.

Org: National Cancer Center Hospital East, Kashiwa, Japan, Kashiwa-Shi, Japan Association for Development of Community Medicine, Graduate School of Medicine Chiba University, Chiba, Japan,

Abstract

First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.

Org: Memorial Sloan Kettering Cancer Center, Macquarie University, Volga District Medical Center, Federal Medical-Biological Agency, Medical Oncology Group,

Abstract

Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial.

Org: Guangxi Medical University Cancer Hospital, Nanning, China, China National Biotec Group, Nnanning,

Abstract

Uncovering mechanisms of response of pembrolizumab and lenvatinib for the treatment of platinum-resistant high grade serous ovarian cancer.

Org: University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Houston, University of Texas - M. D. Anderson Cancer Center,

Abstract

Early experience with nivolumab, gemcitabine, and lenvatinib for fibrolamellar hepatocellular carcinoma.

Org: FibroFighters Foundation, River Forest, IL, Rush University Medical Center, Chicago, IL, University of Zürich,

Abstract

ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM).

Org: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Myeloma, Memorial Sloan Kettering Cancer Center, Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan,

Abstract

PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.

Org: Institut Curie, Saint Cloud, France, Curie Institute, Department of Drug Development and Innovation (D3i),

Abstract

First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Org: BeiGene (Shanghai) Co., Ltd. Shanghai, China, BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene USA, Inc., San Mateo, CA,

Abstract

Efficacy and safety of switching other tyrosine kinase inhibitors to regorafenib combined with primary PD-1 antibodies in patients with hepatocellular carcinoma.

Org: Capital Medical University, Department of Human Cell Biology and Genetics, Southern University of Science and Technology School of Medicine, Department of Infectious Diseases, The Fifth Medical Center of PLA General Hospital,

Abstract

Efficacy and safety of tislelizumab combined with lenvatinib and FOLFOX4-HAIC in conversion therapy of middle-advanced stage hepatocellular carcinoma (HCC): A real-world retrospective study.

Org: The Second Affiliated Hospital of Air Force Medical University, Xi'an Medical College,

Abstract

Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy in combination with lenvatinib and PD-1 inhibitors.

Org: The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Sun Yat-sen University State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Genecast Biotechnology Co., Ltd, Beijing, China,

Abstract

The emerging use of immunotherapy as a treatment option in metastatic renal cell carcinoma: Real-world evidence from a single UK tertiary cancer centre.

Org: Hull University Teaching Hospitals NHS Trust, University of Leeds, Royal Cornwall Hospital NHS Trust,

Abstract

TIPS combined with lenvatinib and PD-1 inhibitor in patients with advanced HCC with symptomatic portal hypertension: A retrospective study.

Org: Sun Yat-sen University Cancer Center, Guangzhou, China,

Abstract

Clinical outcomes in patients with radioiodine refractory thyroid carcinoma treated with dose-reduced lenvatinib.

Org: Rush University Medical Center,

Abstract

A retrospective study exploring the safety and efficacy of hepatic arterial infusion chemotherapy and sequential transarterial embolization combined with lenvatinib and tislelizumab in unresectable hepatocellular carcinoma.

Org: Guangxi Medical University Cancer Hospital, Nanning, China,

Abstract

Clinical efficacy and safety of immune checkpoint inhibitor in combination with regorafenib therapy as second⁃line regimen for patients with unresectable hepatocellular carcinoma.

Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Shandong Cancer Hospital and Institute, Jinan, shandong, China, Shandong Cancer Hospital and Institute, Jinan, China,

Abstract

Comparative efficacy and safety of anti-PD-1/L1 antibody plus anti-VEGF antibody and anti-PD-1/L1 antibody plus VEGFR-targeted tyrosine kinase inhibitor as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A systematic review and network meta-analysis.

Org: Chinese Academy of Sciences, Zhejiang Chinese Medical University,

Abstract

Nivolumab usage patterns combined with TKI for mRCC: Financial toxicity and clinical outcomes from self-paying patients in India—Is low dose an option when access is limited?

Org: Christian Medical College & Hospital Vellore, Christian Medical College Vellore, Department of Uro-Oncology, Chongqing University Cancer Hospital, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,

Abstract

Clinical characteristics and initial treatment patterns of patients with HCC in Korea: A multi-center real-world database analysis from the LINK research network.

Org: Real-World Evidence Team, ALYND, Yonsei University Health System, Seoul, South Korea, IQVIA Solutions Korea Ltd, Seoul, South Korea, IQVIA Solutions Asia Pte Ltd, Singapore, Singapore,

Abstract

Biliary intervention combined with lenvatinib+ PD-1 inhibitor of Klatskin tumor complicated with malignant obstructive jaundice.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,

Abstract

Portal hemodynamic effects of different TKIs in patients with advanced hepatocellular carcinoma: A prospective cohort study.

Org: Comprehensive HCC Center, The Fifth Medical Center of the PLA General Hospital, Senior Department of Hepatology, The 5th Medical Center of the PLA General Hospital,

Abstract

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma.

Org: The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, National Center for Liver Cancer,

Abstract

Sequential therapy versus first-line tyrosine kinase inhibitor plus immune checkpoint inhibitor therapy for unresectable hepatocellular carcinoma.

Org: The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, Shanghai, China, Department of Special Treatment I and Liver Transplantation, Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, Shanghai, China, Shanghai Hongkou Center for Disease Control and Prevention, Shanghai, China, Department of Vascular Surgery, Changzheng Hospital, the Naval Medical University, Shanghai, China, The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, Shanghai, China,

Abstract

Efficacy and safety of regorafenib + PD-1 inhibitor combined with local therapy as second-line treatment in patients with advanced hepatocellular carcinoma: A multicenter retrospective real-world study.

Org: Sun Yat-sen University Cancer Center, Guangzhou, China,

Abstract

Evaluating triple therapy with lenvatinib, PD-1 inhibitor and transarterial chemoembolization for unresectable intrahepatic cholangiocarcinoma: A retrospective study.

Org: The Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China,

Abstract

Anti-PD1 antibody pucotenlimab in combination with bevacizumab or lenvatinib in a phase II study for the treatment of advanced hepatocellular carcinoma (aHCC).

Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, The central hospital of lishui city, Lishui, China, Department of Gastroenterology,Harbin Medical University Cancer Hospital, Harbin, China, Hunan Provincial People's Hospital, Changsha, China,

Abstract

Introducing yttrium-90 radioembolization to atezolizumab and bevacizumab regimen for intermediate and advanced stage hepatocellular carcinoma: A preliminary report of safety and effectiveness.

Org: University of Chicago Medical Center, Chicago, IL, Chicago, IL, Ascension Providence Hospital, Southfield, MI, University of Chicago,

Abstract

Retrospective analysis of the multikinase inhibitor (MKI) pazopanib in differentiated thyroid carcinoma (DTC) in the beyond-first-line setting.

Org: Mayo Clinic, University of Missouri–Kansas City, Mayo Clinic Florida,

Abstract

Treatment patterns post atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: Real-world analysis at Veterans Health Administration comparing lenvatinib vs. sorafenib.

Org: Univeristy of Texas Health Science Center San Antonio, San Antonio, TX, University of Texas Health Science Center at San Antonio, San Anonio, TX, The University of Texas Health Science Center-San Antonio,

Abstract

Real-world experience with atezolizumab plus bevacizumab in the management of non-resectable hepatocellular carcinoma refractory to first-line systemic therapy: Review of literature.

Org: Feist-Weiller Cancer Center at LSUHSC-Shreveport, LSU Health Shreveport, Ochsner LSU Health, Merit health, LSUHSC-S,

Abstract

Therapeutic outcomes of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.

Org: University of Texas MD Anderson Cancer Center, Houston, TX, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, JCCR, Varanasi, India, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo University, Cairo, Egypt,

Abstract

A prospective, single-arm, phase II clinical study of tislelizumab in combination with lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with high risk of recurrence.

Org: Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China,

Abstract

Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: A retrospective analysis.

Org: Harbin Medical University Cancer Hospital, Harbin, China,

Abstract

Pembrolizumab immunotherapy in advanced and recurrent/metastatic salivary gland carcinoma (R/M SGC): A systematic review and meta-analysis.

Org: Federal University of Pelotas, Pelotas, Brazil, Brazil, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil,

Abstract

Hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for advanced hepatocellular carcinoma (aHCC) with Vp3-4 portal vein tumor thrombosis (PVTT): A single-arm, phase II study.

Org: The Second Affiliated Hospital Of Nanchang University, Nanchang, China National Biotec Group,

Abstract

Development of a kidney cancer ex vivo tumor model and image-based artificial intelligence tool for precision immunotherapy and combination therapy testing.

Org: Ourotech Ltd t/a Pear Bio, Royal Free London NHS Foundation Trust,

Abstract

Correlations between overall response rate, progression-free survival and overall survival with kinase inhibitors in radioiodine-refractory differentiated thyroid cancers: A systematic review and meta-analysis.

Org: One Brooklyn Health/Brookdale University Hospital and Medical Center, Brooklyn ImmunoTherapeutics, Nykode Therapeutics,

Abstract

Treatment with lenvatinib plus pembrolizumab in recurrent or advanced endometrial cancer: A systematic review and meta-analysis.

Org: Federal University of Pará - UFPA, Belem, Brazil, Princess Margaret Hospital, Toronto Allergy and Asthma Centre,

Abstract

Efficacy and safety of transarterial chemoembolization in combination with lenvatinib and tislelizumab for patients with unresectable BCLC-B stage hepatocellular carcinoma classified as beyond up to seven criteria: A retrospective study.

Org: Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center and Sun Yat-sen University State Key Laboratory of Oncology in South China, and Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China,

Abstract

The utilization of lenvatinib with pembrolizumab for the treatment of recurrent endometrial cancer.

Org: Northwell Health Cancer Institute, Northwell Health, New Hyde Park, NY,

Abstract

Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study).

Org: Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital Southern Medical University, Guangzhou, China, Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China,

Product

lenvatinib plus pembrolizumab

Abstract

Clinical utility of an international multidisciplinary virtual tumor board for fibrolamellar carcinoma.

Org: FibroFighters Foundation, Rush University Medical Center, University of Zürich, Columbia University - Mailman School of Public Health, UPMC Health Plan,